Publications
A judge blocked the FDA’s plan to regulate LDTs. What now?
Quoted, MedTech Dive
Chad Landmon, Hatch-Waxman & Biologics Chair, discusses how its unlikely the FDA will challenge the March 31 federal court decision that overturned its rule claiming authority over LDTs.
